Lindbrook Capital, LLC Ascendis Pharma A/S Transaction History

Lindbrook Capital, LLC

$1.18 Billion
Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Lindbrook Capital, LLC holds 289 shares of ASND stock, worth $39,413. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289

Previous 288 0.35%

Holding current value

$39,413

Previous $39,000 10.26%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$113.0 - $153.43 $113 - $153	1 Added 0.35%	289 $43,000
Q2 2024 Jul 31, 2024	SELL	$121.07 - $153.67 $121 - $153	-1 Reduced 0.35%	288 $39,000
Q1 2024 Apr 25, 2024	BUY	$123.45 - $159.4 $123 - $159	1 Added 0.35%	289 $43,000
Q4 2023 Jan 31, 2024	BUY	$86.1 - $127.36 $430 - $636	5 Added 1.77%	288 $36,000
Q3 2023 Oct 25, 2023	SELL	$86.5 - $103.97 $1,211 - $1,455	-14 Reduced 4.71%	283 $26,000
Q2 2023 Jul 28, 2023	SELL	$69.96 - $97.84 $10,983 - $15,360	-157 Reduced 34.58%	297 $26,000
Q1 2023 Apr 26, 2023	SELL	$104.9 - $126.78 $8,392 - $10,142	-80 Reduced 14.98%	454 $48,000
Q4 2022 Jan 24, 2023	BUY	$99.42 - $131.97 $4,275 - $5,674	43 Added 8.76%	534 $0
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $1,848 - $2,425	-22 Reduced 4.29%	491 $51,000
Q2 2022 Aug 01, 2022	BUY	$78.08 - $117.61 $9,057 - $13,642	116 Added 29.22%	513 $48,000
Q1 2022 Apr 21, 2022	SELL	$102.18 - $135.75 $102 - $135	-1 Reduced 0.25%	397 $47,000
Q4 2021 Jan 18, 2022	SELL	$127.1 - $169.66 $16,141 - $21,546	-127 Reduced 24.19%	398 $54,000
Q3 2021 Nov 05, 2021	SELL	$112.67 - $176.92 $1,352 - $2,123	-12 Reduced 2.23%	525 $84,000
Q2 2021 Jul 27, 2021	BUY	$121.62 - $145.29 $11,797 - $14,093	97 Added 22.05%	537 $71,000
Q1 2021 Apr 28, 2021	BUY	$124.92 - $173.33 $3,497 - $4,853	28 Added 6.8%	440 $57,000
Q4 2020 Jan 27, 2021	BUY	$151.2 - $182.76 $453 - $548	3 Added 0.73%	412 $69,000
Q3 2020 Nov 03, 2020	BUY	$134.29 - $154.32 $13,294 - $15,277	99 Added 31.94%	409 $63,000
Q2 2020 Jul 27, 2020	SELL	$110.87 - $156.01 $11,087 - $15,601	-100 Reduced 24.39%	310 $46,000
Q1 2020 Apr 22, 2020	SELL	$97.01 - $145.11 $52,579 - $78,649	-542 Reduced 56.93%	410 $46,000
Q4 2019 Jan 27, 2020	BUY	$91.45 - $139.12 $9,145 - $13,912	100 Added 11.74%	952 $132,000
Q3 2019 Oct 31, 2019	BUY	$95.8 - $118.9 $37,074 - $46,014	387 Added 83.23%	852 $82,000
Q2 2019 Jul 24, 2019	SELL	$107.11 - $132.09 $21,422 - $26,418	-200 Reduced 30.08%	465 $53,000
Q1 2019 Apr 23, 2019	SELL	$62.15 - $129.99 $12,430 - $25,998	-200 Reduced 23.12%	665 $78,000
Q4 2018 Feb 07, 2019	BUY	$55.16 - $69.67 $47,713 - $60,264	865 New	865 $54,000

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Ascendis Pharma A/S Transaction History